18 MESES DE OS . SMALL CELL LUNG CÁNCER EN SEGUNDA LÍNEA . NUEVA ESPERANZA EN EL HORIZONTE PARA LOS PACIENTES . BRISTOL MYERS OBTIENE UNA SUPERVIVENCIA GENERAL ( OVERALL SURVIVAL - OS ) DE 18 MESES ... Con su ANTICUERPO GM1 Combinado Con OPDIVO ( NIVOLUMAB ) .

NEW HOPE ON THE HORIZON FOR PATIENTS WITH SCLC .

Ariel Lopez-Chavez, MD

Ariel Lopez-Chavez, MD, Medical Oncologist, Director Of Precision Medicine And Developmental Therapeutics at Allegheny Health Network Cancer Institute, Discusses Ongoing Research In The SMALL CELL LUNG CÁNCER ( SCLC ) Space .

Trials Are Currently Ongoing, Investigating Novel Agents For The Potential Treatment Of SCLC . Investigators On These Studies Aim To Address The High Unmet Needs In SCLC .

Lopez-Chavez Discusses Promising NEW Avenues For SCLC Treatment, Including With An Investigational GM1 ANTIBODY By Bristol Myers Squibb Which Showed Encouraging Results In COMBINATION With NIVOLUMAB ( OPDIVO ) in the SECOND-LINE Setting .

The Agent Achieved An 18-Month Median OVERALL SURVIVAL And Trials Are Ongoing For Its Use In Both Frontline And Combination With STANDAR CHEMOTHERAPY PLUS 

NIVOLUMAB .

Additionally, Lopez-Chavez Highlights The Potential of Radionuclide Therapy For Frontline SCLC And The Exploration Of Cellular Therapies, Which Are Similar To Those Being Investigated in the NON-SMALL CELL LUNG CÁNCER Space .

TRANSCRIPTIÓN : 0:09 | 

There Are Ones That Are Currently Going Towards Registration … And We Have Another GM1 ANTIBODY By [ Bristol Myers Squibb ] .

That One Looked Interesting In Their Initial Results In The Refractory Setting .

 In Particular, When They Combined That With NIVOLUMAB [ OPDIVO ] In The SECOND-LINE Setting, They Got a MEDIAN OVERALL SURVIVAL of Around 18 Months, Which Was Encouraging .

They Are Bringing it Into The Frontline Setting As Well .

They Are Also Studying It In Combination With CARBOPLATIN, ETOPÓSIDE, And NIVOLUMAB .The Results Were Not As Impressive As With The Latter, But It Is Something To Follow-Up On .

1:09 | We Also Have Radionuclide Therapy Also Coming Into The Frontline Setting … On More Space That I Am Interested In Is The Use Of Cellular Therapies . A Lot Of Companies Are Going In The Space Of Cellular Therapies, In Solid Tumors, In Particular In NON-SMALL CELL LUNG CÁNCER, And There Are Some Studies Now Going Into SMALL CELL LUNG CÁNCER . That Will Be Interesting To See What Therapies Are Capable Of .